KR20080042045A - 포유동물로의 인터페론 전달용 지질 구조물 - Google Patents

포유동물로의 인터페론 전달용 지질 구조물 Download PDF

Info

Publication number
KR20080042045A
KR20080042045A KR1020077029917A KR20077029917A KR20080042045A KR 20080042045 A KR20080042045 A KR 20080042045A KR 1020077029917 A KR1020077029917 A KR 1020077029917A KR 20077029917 A KR20077029917 A KR 20077029917A KR 20080042045 A KR20080042045 A KR 20080042045A
Authority
KR
South Korea
Prior art keywords
interferon
lipid
construct
biotin
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077029917A
Other languages
English (en)
Korean (ko)
Inventor
존 알. 라우
더블유. 블레어 지호
Original Assignee
에스디지,인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/384,575 external-priority patent/US20070218117A1/en
Application filed by 에스디지,인코포레이티드 filed Critical 에스디지,인코포레이티드
Publication of KR20080042045A publication Critical patent/KR20080042045A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020077029917A 2005-05-23 2006-05-16 포유동물로의 인터페론 전달용 지질 구조물 Withdrawn KR20080042045A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68387805P 2005-05-23 2005-05-23
US60/683,878 2005-05-23
US11/384,575 US20070218117A1 (en) 2006-03-20 2006-03-20 Supra molecular construct for delivery of interferon to a mammal
US11/384,575 2006-03-20

Publications (1)

Publication Number Publication Date
KR20080042045A true KR20080042045A (ko) 2008-05-14

Family

ID=37452604

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077029917A Withdrawn KR20080042045A (ko) 2005-05-23 2006-05-16 포유동물로의 인터페론 전달용 지질 구조물

Country Status (6)

Country Link
EP (1) EP1883395A4 (enExample)
JP (1) JP2008542270A (enExample)
KR (1) KR20080042045A (enExample)
AU (1) AU2006249479A1 (enExample)
CA (1) CA2609376A1 (enExample)
WO (1) WO2006127360A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022114908A1 (ko) * 2020-11-27 2022-06-02 (주)디앤디파마텍 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체의 경구 제형
WO2022112849A1 (ko) * 2020-11-27 2022-06-02 (주) 디앤디파마텍 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018609A1 (en) * 2007-08-03 2009-02-12 Biotrom Limited Hepatitis c antiviral compositions and methods
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
BRPI0820791A2 (pt) * 2007-12-17 2015-06-16 Lux Innovate Ltd Composições e métodos para manutenção de sistemas de condução e contenção de fluido
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
CN111690539A (zh) * 2020-07-07 2020-09-22 安徽农业大学 高效秸秆纤维素分解菌的筛选及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
GB9426484D0 (en) * 1994-12-08 1995-03-08 Ciba Geigy Ag Compositions
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022114908A1 (ko) * 2020-11-27 2022-06-02 (주)디앤디파마텍 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체의 경구 제형
WO2022112849A1 (ko) * 2020-11-27 2022-06-02 (주) 디앤디파마텍 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체
GB2616223A (en) * 2020-11-27 2023-08-30 D&D Pharmatech Inc Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
GB2617717A (en) * 2020-11-27 2023-10-18 D&D Pharmatech Inc Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
AU2021385222A9 (en) * 2020-11-27 2025-03-20 D&D Pharmatech Inc. Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
AU2021386899B2 (en) * 2020-11-27 2025-05-15 D&D Pharmatech Inc. Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
AU2021385222B2 (en) * 2020-11-27 2025-05-29 D&D Pharmatech Inc. Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto

Also Published As

Publication number Publication date
WO2006127360A2 (en) 2006-11-30
CA2609376A1 (en) 2006-11-30
WO2006127360A3 (en) 2008-01-10
EP1883395A4 (en) 2012-07-04
AU2006249479A1 (en) 2006-11-30
EP1883395A2 (en) 2008-02-06
JP2008542270A (ja) 2008-11-27

Similar Documents

Publication Publication Date Title
EP2205217B1 (en) Orally bioavailable lipid-based constructs
JP5798999B2 (ja) ペプチドおよびタンパク質の薬学的因子の精製および安定化
US9943602B2 (en) Orally bioavailable lipid-based constructs
KR20080042045A (ko) 포유동물로의 인터페론 전달용 지질 구조물
US20070218117A1 (en) Supra molecular construct for delivery of interferon to a mammal
US20100129428A1 (en) Supra molecular construct for delivery of interferon to a mammal
CA2864366C (en) Lipid construct comprising an amphipathic lipid, cholesterol, dicetyl phosphate, and a hepatocyte receptor binding molecule
HK1259503A1 (en) Orally bioavailable lipid-based constructs
ES2675042T3 (es) Constructo lipídico para la administración de insulina a un mamífero
CN104136038A (zh) 体腔积液抑制剂
HK1116396B (en) Lipid construct for delivery of insulin to a mammal
HK1262603B (en) Lipid construct for delivery of insulin to a mammal
HK1262603A1 (en) Lipid construct for delivery of insulin to a mammal

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid